Revising Directive’s Time-of-Use Clause May Cause Reclassification of Devices
March 9, 2010 – 10:28 pmMedical device manufacturers are required to comply with Medical Devices Directive 93/42/EEC as amended by Directive 2007/47/EC by 21 March 2010. Despite having made every effort to meet the essential requirements, companies may be surprised to learn that the classification of some of their devices may be challenged, writes René Clément, co-chairman of Medimark Europe, in an article in the forthcoming Consultants Corner electronic newsletter. Specifically, Annex IX of the Directive places a special emphasis on a new definition of a device’s time of use. The implications of this shift for manufacturers were discussed during a recent meeting with French competent authority Afssaps. Read more…




If you have not yet paid a visit to Eucomed’s 
From the Wire: Researchers at
The European intravenous (IV) therapy and enteral nutrition devices market currently offers med-tech companies a highly lucrative environment, according to new analysis from Frost & Sullivan (F&S). The market is expected to grow to US$2981.2 million in 2012, up from US$2423.0 million in 2008. This is being driven by the increasing number of drug therapies that can employ IV devices and the now proven ability that IV therapy can be administered safely and effectively in the home. In addition, the ability to administer IV therapy safely and effectively in the home has been proven, and European hospital now are focused on downsizing and reducing the time spent by patients in hospitals, which has raised the value of homecare in Europe. 


